Learn More
The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours. In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control. In vivo angiogenesis assay utilising gelfoam sponges,(More)
7358 Background: NSCLC is one of the leading causes of cancer-related deaths world wide. Targretin® (bexarotene) is a selective RXR agonist approved for the treatment of CTCL. Bexarotene has also shown phase I/IIa activity by enhancing survival and delaying progression in NSCLC patients (Clin Cancer Res 5:1658, 1999; J Clin Oncol 19:2626, 2001). METHODS(More)
2057 Background: Bexarotene (BEX) is a retinoid X receptor selective drug approved for treatment of CTCL and has activity in various cancers. Here we evaluate its effect on acquired drug resistance towards gemcitabine (GEM) in Calu3 NSCLC models. METHODS Parental or GEM-resistant Calu3 NSCLC cells were treated with BEX and GEM as single agents or in(More)
17073 Background: Gefitinib and erlotinib, small molecule inhibitors of the EGFR-tyrosine kinase (EGFR-TKI), can have antitumor activity in patients with advanced NSCLC. However, analysis of clinical samples and in vitro characterization of NSCLC cell lines has revealed EGFR mutations that correlate with the clinical responses. While EGFR-mutant cell lines(More)
  • 1